Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
AssigneeRigshospitalet
InventorsClaus Henrik Nielsen, Christian Enevold
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for predicting the response of patients to treatment with Interleukin-6 Receptor (IL6R) inhibitors, such as antibodies directed against the IL6R. The method comprises the analysis of one or more genetic variations, in particular single nucleotide polymorphisms, in or associated with the Interleukin-6 Receptor gene. The present invention further relates to a kit for use in predicting the response of patients to treatment with IL6R inhibitors, such as Tocilizumab. The patients suffers from rheumatoid arthritis.
Claims23
A method for predicting the response of a patient to treatment with an Interleukin 6 Receptor inhibitor comprising the analysis of one or more genetic variations in the Interleukin 6 Receptor gene, the method comprising the steps of:
- i) obtaining a sample of genomic DNA from the patient;
- ii) detecting at least one genetic variation in the Interleukin 6 Receptor gene in said sample;
- and
- iii) predicting whether said patient is a responder, a non-responder or a partial responder.
The method of claim 0, wherein said genetic variation is one or more single nucleotide polymorphisms, said polymorphism selected from the group consisting of rs12083537, rs7526293, rs2228145, rs4129267, rs4509570, rs8192282, rs11557725, rs11557724, rs952146, rs17654071, rs6427631, rs2054855, rs4845615, rs1552481, rs4845617, rs746475, rs6427641, rs11265610, rs1386821, rs7411976, rs4075016, rs4075015, rs12090237, rs4601580, rs6684439, rs4845618, rs6427658, rs6694817, rs28730733, rs7549250, rs7553796, rs7518199, rs4845371, rs6667434, rs4553185, rs4845622, rs4393147, rs4453032, rs6664201, rs4845623, rs4537545, rs7529229, rs4845625, rs4845626, rs6689393, rs4845374, rs28730735, rs28730736, rs11265618, rs12125954, rs10159236, rs10752641, rs4329505, rs4240872, rs4341355, rs2229238, rs7514452, rs4072391, rs4379670 and rs11265621.
7-8. (canceled)
The method of claim 0, wherein the disease is rheumatoid arthritis.
(canceled)
The kit according to claim 0, wherein the inhibitor of the Interleukin 6 Receptor is Tocilizumab.
A method for treatment of a patient for a disease involving the IL6R, said patient predicted to be responder or a partial responder to Tocilizumab, comprising:
- administering Tocilizumab to said patient.
Dependencies are inferred from the claim text.